




RealRate

PHARMACEUTICAL 2017

PUMA BIOTECHNOLOGY INC.
Rank 261 of 313



RealRate

• Financial Strength Rankings using Artificial Intelligence

• www.realrate.ai



RealRate

PHARMACEUTICAL 2017

PUMA BIOTECHNOLOGY INC. Rank 261 of 313



The relative strengths and weaknesses of PUMA BIOTECHNOLOGY INC. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of PUMA BIOTECHNOLOGY INC. compared to the market average is the variable Other Expenses, increasing the Economic Capital Ratio by 79% points. The greatest weakness of PUMA BIOTECHNOLOGY INC. is the variable Research and Development, reducing the Economic Capital Ratio by 373% points.

The company's Economic Capital Ratio, given in the ranking table, is -602%, being 185% points below the market average of -417%.

| Input Variable | Value in 1000 USD |
|---|-------------------|
| Assets, Current | 236,474 |
| Cost of Goods Sold | 0 |
| Intangible Assets | 0 |
| Liabilities, Current | 37,461 |
| Liabilities, Non-Current | 0 |
| Other Assets | 11,163 |
| Other Compr. Net Income | 134 |
| Other Expenses | 0 |
| Other Liabilities | 5,505 |
| Other Net Income | 585 |
| Property and Equipment | 5,153 |
| Research and Development | 222,798 |
| Revenues | 0 |
| Selling, General and Administrative Expense | 53,798 |

| Output Variable | Value in 1000 USD |
|--------------------------|-------------------|
| Assets | 252,790 |
| Liabilities | 42,966 |
| Expenses | 276,596 |
| Stockholders Equity | 209,824 |
| Net Income | -276,011 |
| Comprehensive Net Income | -275,944 |
| Economic Capital Ratio | -602% |



RealRate

• Financial Strength Rankings using Artificial Intelligence • www.realrate.ai